= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Chaudhari

MSACL 2018 EU Abstract

Topic: Proteomics

Podium Presentation in the Ether on Thursday at 11:20 (Chair: Renee Ruhaak)

Combination of Stable Labelled Antibodies and LC-MS to Accurately Quantify Therapeutic Monoclonal Antibodies in the Clinical Laboratory

Ravindra Chaudhari (Presenter)
PROMISE Advanced Proteomics

Authors: Dorothée LEBERT1, Guillaume PICARD1, Ravindra CHAUDHARI1, Aurélien MILLET2, Jérôme GUITTON2, Jean-François JOURDIL3, Françoise STANKE3.
1 Promise Advanced Proteomics, F-38040, Grenoble, France 2 Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Laboratoire de pharmaco-toxicologie, F-69495, Pierre Bénite, France. 3 CHU Grenoble, Laboratoire de pharmaco-toxicologie, F-38000, Grenoble, France

Abstract

We will present an innovative and generic approach involving the use of stable isotope labeled mAbs used as internal standards and LC-MS to allow accurate, sensitive and specific quantification, as required for therapeutic drug monitoring. Our approach was already tested and implemented with success in pharmacology laboratories on anti-TNF antibodies (Infliximab and Adalimumab) and was recently implemented for monitoring Cetuximab.


Financial Disclosure

DescriptionY/NSource
GrantsyesPROMISE Advanced Proteomics
SalaryyesPROMISE Advanced Proteomics
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

yes